Study: Common HIV Drug May Boost Suicide Risk
Patients taking efavirenz should be assessed for depression, researchers say
By Alan Mozes
MONDAY, June 30, 2014 (HealthDay News) -- A medication commonly used to treat HIV appears to double the risk that patients will develop suicidal thoughts or take their lives, new research contends.
The finding concerns the anti-HIV drug efavirenz, which is marketed as Sustiva.
Prior investigations indicated that efavirenz might boost suicide risk because of a negative impact on the central nervous system. The new investigation is the first to pinpoint a link to suicidal thoughts, attempts and completion, the researchers said.
"Efavirenz is a very important and effective antiretroviral medication that is the foundation for much of HIV therapy worldwide," said study co-author Dr. Joseph Eron, of the University of North Carolina Center for AIDS Research at Chapel Hill.
"Our study demonstrated a clear association between efavirenz and suicidality," he said.
Although that risk seems very small, he said, it appears to be persistent, lasting as long as patients take the drug. Antiretroviral treatment typically is lifelong, helping people with the AIDS-causing virus live healthier lives.
"Clinicians should be aware of this ongoing risk, and talk to their patients to assess suicidality," Eron added. That means looking for any history of depression or suicidal thoughts or attempts, the study noted.
For the study, published in the July issue of Annals of Internal Medicine, the researchers analyzed data from four previous antiretroviral investigations conducted between 2001 and 2010.
Nearly three-quarters of study participants were men, with an average age of 37. Roughly one-third had a history of psychiatric problems or had been treated with some form of psychiatric medication in the month before joining one of the studies.
Taken together, more than 3,200 HIV patients had been receiving treatment that included efavirenz, while nearly 2,100 were taking antiretroviral combinations that didn't include the drug.
Patients were tracked for a little less than two years on average.
The research team concluded that the risk for suicide among the efavirenz group was roughly twice that of the non-efavirenz group.
Suicide risk was observed for 62 patients, 47 of whom were taking efavirenz, the study authors reported.